NONHUMAN PRIMATE CORE HUMORAL IMMUNOLOGY LABORATORY FOR AIDS VACCINE RESEARCH AND DEVELOPMENT (COVID-19)

国家过敏和传染病研究所(NIAID)艾滋病(DAIDS)司的任务是通过支持可导致开发疗法、疫苗和预防战略的研究，确保结束人类免疫机能丧失病毒/获得性免疫机能丧失综合症(HIV/AIDS)流行病。非人灵长类动物(NHP)模型提供了测试各种候选艾滋病疫苗的机会，优化了它们诱导免疫反应的能力，并测试了它们在病毒攻击后预防感染或控制病毒复制的能力。DAIDS为NIAID的猿猴疫苗评估组(SVEU)合同地点进行的NHP研究提供免疫学和病毒学支持，并通过三个非人类灵长类免疫学和艾滋病疫苗研发病毒学实验室(NHP核心实验室)合同为艾滋病疫苗研究人员提供支持。这些核心实验室的目标是确保为临床前NHP研究进行的分析的标准化和可比性，并为评估候选艾滋病毒和SIV疫苗的免疫原性和有效性提供共同的基础。该项目特别关注SARS-CoV-2(新冠肺炎)中和试验和其他试验，以评估NHP对候选SARS-CoV-2疫苗的抗体应答。

The mission of the Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID) is to ensure an end to the human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) epidemic by supporting research that can lead to the development of therapies, vaccines, and prevention strategies. Nonhuman primate (NHP) models present the opportunity to test a variety of candidate AIDS vaccines, optimizing their ability to elicit immune responses and testing their ability to prevent infection or to control virus replication after virus challenge. DAIDS provides immunological and virological support for NHP studies conducted at NIAID’s Simian Vaccine Evaluation Unit (SVEU) contract sites and by AIDS vaccine researchers through three Nonhuman Primate Immunology and Virology Laboratories for AIDS Vaccine Research and Development (NHP Core Labs) contracts. The objective of these Core Laboratories has been to ensure standardization and comparability of the assays conducted for preclinical NHP studies and to provide a common basis for assessment of the immunogenicity and efficacy of candidate HIV and SIV vaccines. This project focuses specifically on SARS-CoV-2 (COVID-19) neutralization assays and other assays to evaluate antibody responses of NHPs to candidate SARS-CoV-2 vaccines.